Fred Hutch statement on the interim analysis of the Phase 3 trial of the Moderna vaccine against COVID-19

SEATTLE — Nov. 16, 2020 — Dr. Larry Corey, virologist at Fred Hutchinson Cancer Research Center and co-leader of the COVID-19 Prevention Network’s vaccine testing program commented on an interim analysis of the Phase 3 trial of the Moderna vaccine against COVID-19:

We’re optimistic today about the success of the two mRNA vaccine candidates against COVID-19 and the other vaccine candidates in our testing pipeline, all of which target the SARS-CoV-2 spike protein.

These results demonstrate that a single strand of RNA that transcribes a prefusion protein of the SARS CoV-2 virus, when wrapped in a lipid nanoparticle, can elicit a highly effective immune response in adults, among the elderly, and across racial and ethnic populations.

We recognize the tens of thousands of volunteers who made the choice to participate in vaccine clinical trials and helped move the science forward. To immunize the entire global population, we’ll need multiple, successful vaccines. The vaccine trials in our program are ongoing. With this in mind, we encourage you to visit to learn more about our vaccine testing program and how you can help end the uncertainty of this pandemic.


About Fred Hutch

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.


Claire Hudson